Program
ACT-777991
Also written as “ACT-777991 (SAD)”, “ACT-777991 (MAD)” and “14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)”.
Its studies are mostly in Vitiligo, led by Idorsia Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Idorsia Pharmaceuticals | 21 open or running | phase 2since May 11, 2026 | Mar 3, 2021 | Jun 28, 2027phase 2 · NCT07667569 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 3, 2021First study: phase 1 study in HealthyFirst studyNCT04798209 · 70 enrolled · Netherlands
- May 11, 2026Phase 2 study in Non-Segmental VitiligoPhase 2 reachedNCT07667569 · 30 planned · United States, Poland
Ahead
- Jun 28, 2027Primary completion: phase 2 study in Non-Segmental VitiligoNCT07667569
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07667569Non-Segmental Vitiligo · United States, Poland | 2 | Recruiting | Jun 28, 2027 | 30 |
| NCT04798209Healthy · Netherlands | 1 | Completed | Jan 26, 2022 | 70 |
How it is read
Names in the registry
- “ACT-777991”, 1 entry
- “ACT-777991 (SAD)”, 1 entry
- “ACT-777991 (MAD)”, 1 entry
- “14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)”, 1 entry
- “14C-ACT-777991 microtracer (MAD - ADME)”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.